Phase 1 Study Evaluating the Safety and Immunogenicity of COVI-VAC as a Booster Dose in Previously Vaccinated Adults Against COVID-19
Latest Information Update: 18 Jan 2023
At a glance
- Drugs CDX 005 (Primary)
- Indications COVID 2019 infections
- Focus Pharmacodynamics
- Sponsors Codagenix
Most Recent Events
- 11 Jan 2023 Status changed from active, no longer recruiting to completed.
- 24 Jun 2022 Status changed from recruiting to active, no longer recruiting.
- 25 May 2022 According to a Codagenix media release, initial data from the trial are anticipated in August 2022.